Anebulo PharmaceuticalsANEB
ANEB
About: Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
Employees: 2
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
20% more funds holding
Funds holding: 15 [Q4 2024] → 18 (+3) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
21% less capital invested
Capital invested by funds: $37.3M [Q4 2024] → $29.4M (-$7.91M) [Q1 2025]
32.0% less ownership
Funds ownership: 87.04% [Q4 2024] → 55.05% (-32.0%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$3
116%
upside
Avg. target
$3
116%
upside
High target
$3
116%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Michael Okunewitch | 116%upside $3 | Buy Maintained | 15 May 2025 |
Financial journalist opinion
Neutral
Business Wire
1 month ago
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended March 31, 2025, and recent updates. Third Quarter Fiscal Year 2025 and Subsequent Highlights: Anebulo is prioritizing the advancement of an intravenous selonabant as a potential treatment for pediatri.
Neutral
Business Wire
3 months ago
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2024, and recent updates. Second Quarter Fiscal Year 2025 and Subsequent Highlights: In December 2024, Anebulo met with FDA to discuss the development of intravenous selonabant and the in.
Neutral
Business Wire
5 months ago
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise.
Neutral
Business Wire
7 months ago
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates.
Neutral
Business Wire
8 months ago
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates.
Neutral
Business Wire
10 months ago
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), has been awarded the first tranche of a two year cooperative grant of up to approximately $1.9 million from the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health (“NIH”), to support the development of intravenous selonabant.
Neutral
Business Wire
1 year ago
Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development
BOSTON--(BUSINESS WIRE)--Galehead Development, LLC (“Galehead”) and Rivian Automotive, LLC (“Rivian”) have entered into an agreement to collaborate on the development of renewable energy resources tailored to Rivian's locational and environmental priorities. Galehead will develop solar projects with specific consideration for Rivian's “3C” Framework. The 3C Framework is a progressive procurement standard that commits Rivian to sourcing renewable energy from projects that have a measurable posit.
Neutral
Business Wire
1 year ago
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid toxicities that include acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning (the “Company” or “Anebulo”), today announced financial results for the three months ended March 31, 2024, and recent updates. Third Quarter Fiscal Year 2024 and Subsequent Highlights: Anebulo prioritizes deve.
Neutral
Business Wire
1 year ago
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates.
Neutral
Business Wire
1 year ago
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates.
Charts implemented using Lightweight Charts™